A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients

Autoimmunity Reviews

Volumn 14, Issue 2, 2015, Pages 140-152

  Silva, I ^a   Almeida, J ^b   Vasconcelos, C ^a,c  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Autoantibodies; Capillaroscopy; Digital ulcer s; Endothelin 1; Systemic sclerosis; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; AUTOANTIBODY; BIOLOGICAL MARKER; CENTROMERE ANTIBODY; ENDOGLIN; ENDOSTATIN; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN 1; FIBRILLARIN ANTIBODY; N(G),N(G) DIMETHYLARGININE; PLACENTAL GROWTH FACTOR; SCL 70 ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; CAPILLAROSCOPY; CAPILLARY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; FINGER ULCER; HUMAN; ISCHEMIA; MEDLINE; PRACTICE GUIDELINE; PREDICTIVE VALUE; REVIEW; RISK FACTOR; SCAR FORMATION; SCLERODERMA; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM; WEB OF SCIENCE; COMPLICATION; IMMUNOLOGY; ULCER;

AUTOANTIBODIES; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SCLERODERMA, SYSTEMIC; ULCER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922589066     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.10.009     Document Type: Review

References (88)

1. Wollheim F.A. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 2005, 44(10):1212-1216.
2. Chighizola C., Shoenfeld Y., Meroni P.L. Systemic sclerosis. Introduction. Autoimmun Rev 2011, 10(5):239-240.
3. Wigley F.M. Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009, 36(2-3):150-175.
4. Herrick A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012, 8(8):469-479.
5. Ho M., Veale D., Eastmond C., Nuki G., Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis 2000, 59(1):39-43.
6. Herrick A.L. Management of Raynaud's phenomenon and digital ischemia. Curr Rheumatol Rep 2013, 15(1):303.
7. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002, 81(2):139-153.
8. Amanzi L., Braschi F., Fiori G., Galluccio F., Miniati I., Guiducci S., et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) 2010, 49(7):1374-1382.
9. Hutton B., Salanti G., Chaimani A., Caldwell D.M., Schmid C., Thorlund K., et al. The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS One 2014, 9(3):e92508.
10. Walker U.A., Tyndall A., Czirjak L., Denton C., Farge-Bancel D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007, 66(6):754-763.
11. Hachulla E., Clerson P., Launay D., Lambert M., Morell-Dubois S., Queyrel V., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007, 34(12):2423-2430.
12. Sunderkotter C., Herrgott I., Bruckner C., Moinzadeh P., Pfeiffer C., Gerss J., et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009, 160(4):835-843.
13. Tiev K.P., Diot E., Clerson P., Dupuis-Simeon F., Hachulla E., Hatron P.Y., et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIR-Sclerodermie). J Rheumatol 2009, 36(7):1470-1476.
14. Caramaschi P., Martinelli N., Volpe A., Pieropan S., Tinazzi I., Patuzzo G., et al. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol 2009, 28(7):807-813.
15. Steen V., Denton C.P., Pope J.E., Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl. 3:iii):19-24.
16. Khimdas S., Harding S., Bonner A., Zummer B., Baron M., Pope J. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res 2011, 63(1):142-149.
17. Manno R.L., Wigley F.M., Gelber A.C., Hummers L.K. Late-age onset systemic sclerosis. J Rheumatol 2011, 38(7):1317-1325.
18. Denton C.P., Krieg T., Guillevin L., Schwierin B., Rosenberg D., Silkey M., et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis 2012, 71(5):718-721.
19. Simeon-Aznar C.P., Fonollosa-Pla V., Tolosa-Vilella C., Espinosa-Garriga G., Ramos-Casals M., Campillo-Grau M., et al. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum 2012, 41(6):789-800.
20. Bacher A., Mittoo S., Hudson M., Tatibouet S., Baron M. Systemic sclerosis in Canada's North American Native population: assessment of clinical and serological manifestations. J Rheumatol 2013, 40(7):1121-1126.
21. Xu D., Li M.T., Hou Y., Wang Q., Hu C.J., Song N., et al. Clinical characteristics of systemic sclerosis patients with digital ulcers in China. Clin Exp Rheumatol 2013, 31(2 Suppl. 76):46-49.
22. Ennis H., Vail A., Wragg E., Taylor A., Moore T., Murray A., et al. A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol 2013, 42(6):483-486.
23. Poormoghim H., Moghadam A.S., Moradi-Lakeh M., Jafarzadeh M., Asadifar B., Ghelman M., et al. Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int 2013, 33(8):1943-1950.
24. Ferri C., Sebastiani M., Lo Monaco A., Iudici M., Giuggioli D., Furini F., et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 2014, 13:1026-1034.
25. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35(1):35-42.
26. Hanke K., Dahnrich C., Bruckner C.S., Huscher D., Becker M., Jansen A., et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009, 11(1):R28.
27. Muller Cde S., Paiva Edos S., Azevedo V.F., Radominski S.C., Lima Filho J.H. Autoantibody profile and clinical correlation in a group of patients with systemic sclerosis in southern Brazil. Rev Bras Reumatol 2011, 51(4):314-318. [23-4].
28. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12(3):340-354.
29. Jacobsen S., Halberg P., Ullman S., Van Venrooij W.J., Hoier-Madsen M., Wiik A., et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998, 37(1):39-45.
30. Mierau R., Moinzadeh P., Riemekasten G., Melchers I., Meurer M., Reichenberger F., et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011, 13(5):R172.
31. Hudson M., Mahler M., Pope J., You D., Tatibouet S., Steele R., et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012, 39(4):787-794.
32. Koenig M., Dieude M., Senecal J.L. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7(8):588-593.
33. Walker K.M., Pope J. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011, 38(7):1326-1328.
34. Reveille J.D., Fischbach M., McNearney T., Friedman A.W., Aguilar M.B., Lisse J., et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30(5):332-346.
35. Sharif R., Fritzler M.J., Mayes M.D., Gonzalez E.B., McNearney T.A., Draeger H., et al. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol 2011, 38(8):1622-1630.
36. Salojin K.V., Le Tonqueze M., Saraux A., Nassonov E.L., Dueymes M., Piette J.C., et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997, 102(2):178-185.
37. Pignone A., Scaletti C., Matucci-Cerinic M., Vazquez-Abad D., Meroni P.L., Del Papa N., et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998, 16(5):527-532.
38. Sgonc R.G.M., Dietrich H., Recheis H., Gershwin M.E., Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. Clin Investig 1996, 98:785-792.
39. Hanke K., Bruckner C.S., Dahnrich C., Huscher D., Komorowski L., Meyer W., et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 2009, 11(1):R22.
40. Mahler M., Fritzler M.J. The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Res Ther 2009, 11(2):106.
41. Marie I., Jouen F., Hellot M.F., Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 2008, 158(1):141-144.
42. Morrisroe K.B., Stevens W., Nandurkar H., Prior D., Thakkar V., Roddy J., et al. The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis. Clin Exp Rheumatol 2014, [Epub ahead of print].
43. Eloranta M.L., Franck-Larsson K., Lovgren T., Kalamajski S., Ronnblom A., Rubin K., et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010, 69(7):1396-1402.
44. Giuggioli D., Manfredi A., Colaci M., Manzini C.U., Antonelli A., Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013, 12(11):1058-1063.
45. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998, 158(6):595-600.
46. Cutolo M., Smith V. State of the art on nailfold capillaroscopy: a reliable diagnostic tool and putative biomarker in rheumatology?. Rheumatology (Oxford) 2013, 52(11):1933-1940.
47. Rossi D., Russo A., Manna E., Binello G., Baldovino S., Sciascia S., et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013, 12(8):821-825.
48. Caramaschi P., Canestrini S., Martinelli N., Volpe A., Pieropan S., Ferrari M., et al. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology (Oxford) 2007, 46(10):1566-1569.
49. Smith V., Decuman S., Sulli A., Bonroy C., Piettte Y., Deschepper E., et al. Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis 2012, 71(10):1636-1639.
50. Lambova S., Muller-Ladner U. Capillaroscopic findings in systemic sclerosis - are they associated with disease duration and presence of digital ulcers?. Discov Med 2011, 12(66):413-418.
51. Sulli A., Secchi M.E., Pizzorni C., Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008, 67(6):885-887.
52. Alivernini S., De Santis M., Tolusso B., Mannocci A., Bosello S.L., Peluso G., et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009, 60(3):426-435.
53. Smith V., De Keyser F., Pizzorni C., Van Praet J.T., Decuman S., Sulli A., et al. Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 2011, 70(1):180-183.
54. Smith V., Riccieri V., Pizzorni C., Decuman S., Deschepper E., Bonroy C., et al. Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J Rheumatol 2013, 40(12):2023-2028.
55. Sebastiani M., Manfredi A., Colaci M., D'Amico R., Malagoli V., Giuggioli D., et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 2009, 61(5):688-694.
56. Sebastiani M., Manfredi A., Vukatana G., Moscatelli S., Riato L., Bocci M., et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis 2012, 71(1):67-70.
57. Sebastiani M., Manfredi A., Lo Monaco A., Praino E., Riccieri V., Grattagliano V., et al. Capillaroscopic Skin Ulcers Risk Index (CSURI) calculated with different videocapillaroscopy devices: how its predictive values change. Clin Exp Rheumatol 2013, 31(2 Suppl. 76):115-117.
58. Manfredi A., Sebastiani M., Carraro V., Iudici M., Bocci M., Vukatana G., et al. Prediction risk chart for scleroderma digital ulcers: a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters. Clin Hemorheol Microcirc 2014, [Epub ahead of print].
59. Kim H.S., Park M.K., Kim H.Y., Park S.H. Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 2010, 29(3):247-254.
60. Ennis H., Moore T., Murray A., Vail A., Herrick A.L. Further confirmation that digital ulcers are associated with the severity of abnormality on nailfold capillaroscopy in patients with systemic sclerosis. Rheumatology (Oxford) 2014, 53(2):376-377.
61. Cutolo M, Herrick A, Distler O, Becker M, Beltran E, Carpentier P, et al. Nailfold videocapillaroscopy and other predictive factors associated with new digital ulcers in systemic sclerosis. Data from the CAP study. Ann Rheum Dis 2013, 72(S3):146.
62. Cozzani E., Javor S., Laborai E., Drosera M., Parodi A. Endothelin-1 levels in scleroderma patients: a pilot study. ISRN Dermatol 2013, 2013:125632.
63. Aghaei M., Gharibdost F., Zayeni H., Akhlaghi M., Sedighi S., Rostamian A.R., et al. Endothelin-1 in systemic sclerosis. Ind Dermatol Online J 2012, 3(1):14-16.
64. Sulli A., Soldano S., Pizzorni C., Montagna P., Secchi M.E., Villaggio B., et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009, 36(6):1235-1239.
65. Wipff J., Avouac J., Borderie D., Zerkak D., Lemarechal H., Kahan A., et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 2008, 47(7):972-975.
66. Dooley A., Gao B., Bradley N., Abraham D.J., Black C.M., Jacobs M., et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 2006, 45(6):676-684.
67. Silva I., Almeida I., Marinho A., Vasconcelos C. Predictors of digital ulcers in systemic sclerosis: correlation between clinical and hemodynamic features, capillaroscopy, endothelium dysfunction and angiogenesis biomarkers. Arthritis Rheum 2012, 64(Suppl. 10):1483.
68. Barnes T., Gliddon A., Dore C.J., Maddison P., Moots R.J. Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis. Rheumatology (Oxford) 2012, 51(9):1606-1609.
69. Lip G.Y., Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997, 34(2):255-265.
70. Scheja A., Akesson A., Geborek P., Wildt M., Wollheim C.B., Wollheim F.A., et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001, 3(3):178-182.
71. Distler O., Del Rosso A., Giacomelli R., Cipriani P., Conforti M.L., Guiducci S., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4(6):R11.
72. Distler O., Distler J.H., Scheid A., Acker T., Hirth A., Rethage J., et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 95(1):109-116.
73. Solanilla A., Villeneuve J., Auguste P., Hugues M., Alioum A., Lepreux S., et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 2009, 48(9):1036-1044.
74. Bielecki M., Kowal K., Lapinska A., Chwiesko-Minarowska S., Chyczewski L., Kowal-Bielecka O. Peripheral blood mononuclear cells from patients with systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease. Adv Med Sci 2011, 56(2):255-263.
75. Farouk H.M., Hamza S.H., El Bakry S.A., Youssef S.S., Aly I.M., Moustafa A.A., et al. Dysregulation of angiogenic homeostasis in systemic sclerosis. Int J Rheum Dis 2013, 16(4):448-454.
76. Manetti M., Guiducci S., Ibba-Manneschi L., Matucci-Cerinic M. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends cardiovasc Med 2011, 21(7):204-210.
77. Manetti M., Guiducci S., Romano E., Ceccarelli C., Bellando-Randone S., Conforti M.L., et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011, 109(3):e14-e26.
78. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285.
79. Hebbar M., Peyrat J.P., Hornez L., Hatron P.Y., Hachulla E., Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000, 43(4):889-893.
80. Avouac J., Meune C., Ruiz B., Couraud P.O., Uzan G., Boileau C., et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis 2012, 71(3):394-399.
81. Michalska-Jakubus M., Kowal-Bielecka O., Chodorowska G., Bielecki M., Krasowska D. Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford) 2011, 50(4):746-755.
82. Ichimura Y., Asano Y., Akamata K., Aozasa N., Noda S., Taniguchi T., et al. Serum angiopoietin-like protein 3 levels: possible correlation with progressive skin sclerosis, digital ulcers and pulmonary vascular involvement in patients with systemic sclerosis. Acta Derm Venereol 2013, 94:157-162.
83. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28(7):1573-1576.
84. Van Den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013, 65(11):2737-2747.
85. Medsger T.A., Silman A.J., Steen V.D., Black C.M., Akesson A., Bacon P.A., et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999, 26(10):2159-2167.
86. Calixto O.J., Anaya J.M. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev 2014, 13(6):641-654.
87. Mansour S., Bonner A., Muangchan C., Hudson M., Baron M., Pope J.E. Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group. J Rheumatol 2013, 40(4):447-454.
88. Marie I., Gehanno J.F., Bubenheim M., Duval-Modeste A.B., Joly P., Dominique S., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13(2):151-156.